Trial Profile
A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2019
Price :
$35
*
At a glance
- Drugs GEN 003 (Primary) ; Matrix M
- Indications Herpes genitalis; Herpes simplex virus type 2 infections
- Focus Therapeutic Use
- Sponsors Genocea Biosciences [CEASED]
- 15 May 2019 Results published in the Vaccine
- 08 Oct 2017 Results presented at the IDWeek 2017
- 08 Oct 2017 Results assessing immunogenicity responses to GEN-003 through 1 year of follow up presented at the IDWeek 2017